Expanded Access Program of Palopegteriparatide in Patients With Hypoparathyroidism
Condition(s):HypoparathyroidismLast Updated:August 14, 2023Available
Include Studies Not Open or Pending
Condition(s):HypoparathyroidismLast Updated:August 14, 2023Available
Condition(s):AchondroplasiaLast Updated:March 21, 2024Recruiting
Condition(s):Head and Neck NeoplasmsLast Updated:March 25, 2024Recruiting
Condition(s):Advanced Solid Tumor; Locally Advanced Solid Tumor; Metastatic Solid Tumor; Platinum-resistant Ovarian Cancer; Post Anti-PD-1 Melanoma; 2L+ Cervical Cancer; Neoadjuvant Melanoma; Neoadjuvant Non-Small Cell Lung Cancer; Post Anti-PD-(L)1 Non-Small Cell Lung Cancer; Post Anti-PD-(L)1 Small Cell Lung CancerLast Updated:January 3, 2024Recruiting
Condition(s):Advanced Solid Tumor; Locally Advanced Solid Tumor; Metastatic Solid Tumor; Head and Neck Squamous Cell Carcinoma HNSCC; HPV-associated Cancers; Neoadjuvant Melanoma; Neoadjuvant Cutaneous Squamous Cell Carcinoma (cSCC)Last Updated:March 5, 2024Recruiting
Condition(s):Growth Hormone DeficiencyLast Updated:November 7, 2023Recruiting
Condition(s):Growth Hormone DeficiencyLast Updated:January 10, 2024Recruiting
Condition(s):Turner SyndromeLast Updated:March 7, 2024Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.